Z. Eisenstein et al., MODULATION OF THE IL-2 PRODUCTION DEFECT IN-VITRO IN GRAVES-DISEASE, Clinical and experimental immunology, 96(2), 1994, pp. 323-328
IL-2 production by mitogen-induced peripheral blood mononuclear cells
was reported to be reduced in several autoimmune diseases, including G
raves' disease (GD). This production defect in hyperthyroid GD was res
tored to normal by antithyroid drug therapy or during remission. Howev
er, its underlying mechanism and role in the autoimmune process are st
ill uncertain. The present study was undertaken in order to screen the
in vitro IL-2 generating system for putative factors responsible for
its failure, and to see to what extent this was reversible. Thyroid ho
rmone or antithyroid drugs had no effect on IL-2 production in vitro.
Cultures were found to be free of soluble inhibitors of IL-2 productio
n or action. IL-1 deficiency as a cause of the IL-2 defect was ruled o
ut; rather, Graves' adherent cells were found to be activated in being
capable of secreting large amounts of IL-1 and prostaglandin E(2) (PG
E(2)). The latter was not found to be responsible for the decreased IL
-2 production. IL-2 production by Graves' mononuclears was completely
restored to normal by: (i) adherent cell depletion, irradiation or sub
stitution with normal adherent cells; (ii) preincubation of mononuclea
rs for 24-72 h before mitogen stimulation; (iii) the synergistic actio
n of a phorbol ester and a calcium ionophore. These data indicate that
inhibition by activated adherent cells accounts for the in vitro IL-2
production defect in GD. This inhibition is not mediated by soluble f
actors, but probably through direct interaction with the producing cel
ls, and is reversible in rested cultures or through a bypassed signal
transduction.